**
NHS England has announced a temporary halt on new referrals for masculinising or feminising hormone treatments for patients aged 16 and 17. This decision follows a comprehensive review which concluded that there is insufficient clinical evidence to justify the continued use of these treatments for minors experiencing gender incongruence or dysphoria. While current patients can maintain their treatment plans, any new cases will be paused as the health authority reassesses its policies.
Review Findings Prompt Caution
The decision comes in light of a critical report by Hilary Cass, who recommended “extreme caution” regarding hormone therapies for young individuals. Her review highlighted the need for a robust clinical justification before initiating such treatments in this age group, particularly when considering the potential risks involved. NHS England subsequently undertook its own review to evaluate the existing evidence surrounding the application of oestrogen and testosterone in treating gender dysphoria among adolescents.
Prof James Palmer, the national medical director for specialised services at NHS England, stated, “This review has established that the available evidence does not support the continued use of masculinising or feminising hormones to treat gender incongruence or dysphoria for young people under 18.” This assertion has raised significant concerns among advocates and healthcare professionals regarding the implications for the mental and physical health of young trans individuals.
Ongoing Support for Current Patients
Despite the suspension of new referrals, patients under 18 who are already receiving cross-sex hormones will be allowed to continue their treatments. However, these ongoing prescriptions will now be subject to individual reviews with their clinical teams, ensuring that each case is evaluated carefully. NHS England has emphasised its commitment to providing supportive services for minors dealing with gender incongruence, including mental health resources and referrals to specialised gender services.
The announcement coincides with a broader scrutiny of treatments for young people. A clinical trial investigating the effects of puberty blockers on children as young as 10 has also been paused due to concerns about the long-term biological impacts. In 2024, the use of these drugs for under-18s was banned, further complicating the landscape for gender-affirming treatments in the UK.
Public Consultation Underway
In a bid to gather community insights and perspectives, NHS England has initiated a 90-day consultation period concerning the removal of gender-affirming hormone treatments as a standard procedure for minors. This consultation aims to engage healthcare professionals, patients, and the public in discussions about the future of these treatments, before finalising a new policy framework.
Critics of the decision have voiced strong opinions. Tammy Hymas, policy lead at the advocacy group TransActual, condemned the pause on new prescriptions, labelling it a significant infringement on the bodily autonomy of young trans individuals. “This is a profound attack on young people’s bodily autonomy with trans people yet again cruelly singled out by this government,” she asserted.
Conversely, Helen Joyce, director of advocacy at Sex Matters, suggested that the pause comes “too late” for many minors, stressing that under-18s are often ill-equipped to consent to irreversible medical interventions.
Why it Matters
The implications of NHS England’s decision are far-reaching, as they not only affect the immediate access to hormone treatments for young individuals grappling with their gender identity but also reflect a growing caution within the healthcare system regarding the treatment of minors. As the debate over gender-affirming care intensifies, it underscores the need for a balanced approach that respects the rights and health needs of young people while ensuring that medical practices are grounded in solid evidence. This pivotal moment may shape the future of gender care in the UK, influencing policies and practices for years to come.
